SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

• Research type

  Research Study

• Full title

  A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

• IRAS ID

  158485

• Contact name

  George Follows

• Contact email

  george.follows@addenbrookes.nhs.uk

• Eudract number

  2014-001977-15

• Clinicaltrials.gov Identifier

  NCT02227251

• Duration of Study in the UK

  2 years, 7 months, 30 days

• Research summary

  This study aims to assess the safety and efficacy of the study drug Selinexor (KPT­330)in patients with refractory (does not respond to treatment) and or relapsed (disease returns after a period of improvement) Diffuse Large B Cell Lymphoma.

• REC name

  East of England - Cambridge Central Research Ethics Committee

• REC reference

  14/EE/1224

• Date of REC Opinion

  3 Dec 2014

• REC opinion

  Further Information Favourable Opinion